Kenvue Sees Unusually Large Options Volume (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE - Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors bought 53,946 call options on the company. This is an increase of 623% compared to the typical volume of 7,464 call options.

Kenvue Stock Up 4.1 %

Shares of KVUE stock traded up $0.92 during trading hours on Friday, reaching $23.31. The company had a trading volume of 25,659,098 shares, compared to its average volume of 13,792,800. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The business has a fifty day simple moving average of $21.29 and a 200-day simple moving average of $22.14. The company has a market cap of $44.68 billion, a price-to-earnings ratio of 43.97, a price-to-earnings-growth ratio of 2.61 and a beta of 1.45.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, research analysts expect that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.52%. Kenvue's dividend payout ratio (DPR) is currently 154.72%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. Barclays decreased their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. UBS Group decreased their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Finally, Piper Sandler raised Kenvue from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus target price of $23.00.

Institutional Trading of Kenvue

Hedge funds have recently bought and sold shares of the business. Grove Bank & Trust lifted its holdings in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the fourth quarter worth $29,000. SRS Capital Advisors Inc. increased its position in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in Kenvue in the third quarter worth $35,000. Finally, Fortitude Family Office LLC increased its position in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after buying an additional 777 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.